YMX

Entrectinib


Toggle HydrogenToggle Labels

Chemical Component Summary

NameEntrectinib
IdentifiersN-[5-[[3,5-bis(fluoranyl)phenyl]methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
FormulaC31 H34 F2 N6 O2
Molecular Weight560.637
TypeNON-POLYMER
Isomeric SMILESCN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4c5cc(ccc5[nH]n4)Cc6cc(cc(c6)F)F
InChIInChI=1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)
InChIKeyHAYYBYPASCDWEQ-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count75
Chiral Atom Count0
Bond Count80
Aromatic Bond Count22

Drug Info: DrugBank

DrugBank IDDB11986 
NameEntrectinib
Groups
  • investigational
  • approved
DescriptionEntrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor.[L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.[L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.[A183929]
Synonyms
  • N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
  • Entrectinib
Brand NamesRozlytrek
IndicationEntrectinib is indicated for the treatment of metastatic ROS1-positive non-small cell lung cancer in adults.[L8081] Entrectinib is also indicated in adults and children over 12 years old for the treatment of NTRK gene fusion-positive solid tumors which have metastasized or for which surgical resection is likely to result in severe morbidity and for which has progressed on previous therapies or for which no comparable alternative therapies are available. FoundationOne®Liquid CDx is the only FDA-approved test for the detection of ROS1 rearrangement(s) in NSCLC for selecting patients for treatment with entrectinib.[L44518]
Categories
  • Amides
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Benzene Derivatives
  • Cytochrome P-450 CYP3A Substrates
ATC-CodeL01EX14
CAS number1108743-60-7

Drug Targets

NameTarget SequencePharmacological ActionActions
High affinity nerve growth factor receptorMLRGGRRGQLGWHSWAAGPGSLLAWLILASAGAAPCPDACCPHGSSGLRC...unknowninhibitor
NT-3 growth factor receptorMDVSLCPAKCSFWRIFLLGSVWLDYVGSVLACPANCVCSKTEINCRRPDD...unknowninhibitor
Proto-oncogene tyrosine-protein kinase ROSMKNIYCLIPKLVNFATLGCLWISVVQCTVLNSCLKSCVTNLGQQLDLGTP...unknowninhibitor
BDNF/NT-3 growth factors receptorMSSWIRWHGPAMARLWGFCWLVVGFWRAAFACPTSCKCSASRIWCSDPSP...unknowninhibitor
Tyrosine-protein kinase JAK2MGMACLTMTEMEGTSTSSIYQNGDISGNANSMKQIDPVLQVYLYHSLGKS...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL1983268
PubChem 25141092
ChEMBL CHEMBL1983268